Claro Advisors LLC Purchases 374 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Claro Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% during the 2nd quarter, Holdings Channel reports. The fund owned 7,368 shares of the biopharmaceutical company’s stock after purchasing an additional 374 shares during the period. Claro Advisors LLC’s holdings in Gilead Sciences were worth $506,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Private Wealth Management Group LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at $29,000. CarsonAllaria Wealth Management Ltd. increased its holdings in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 238 shares during the last quarter. Sachetta LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $30,000. Palisade Asset Management LLC bought a new position in shares of Gilead Sciences in the 1st quarter valued at about $29,000. Finally, Gladius Capital Management LP purchased a new position in Gilead Sciences in the fourth quarter worth about $34,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $71.00 to $72.00 and gave the stock a “sector perform” rating in a research note on Friday, August 9th. Truist Financial increased their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Finally, Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.94.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.6 %

Shares of NASDAQ GILD opened at $79.00 on Monday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The firm has a market capitalization of $98.35 billion, a price-to-earnings ratio of 219.44, a PEG ratio of 2.74 and a beta of 0.18. The stock has a 50 day moving average price of $73.10 and a 200 day moving average price of $70.31. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Sell-side analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.90%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.